Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novavax Amex: NOX. Great news to open monday morning -- Ignore unavailable to you. Want to Upgrade?

To: Matt Webster who wrote (22)	10/2/1998 12:05:00 PM
From: PHarris	Read Replies (1) \| Respond to of 38

MORE NEWS.... Friday October 2, 11:00 am Eastern Time Company Press Release SOURCE: Novavax, Inc. Novavax Repurchases $5.0 Million Series A Custom Convertible Preferred Stock COLUMBIA, Md., Oct. 2 /PRNewswire/ -- Novavax, Inc. (Amex: NOX - news), announced today that it has entered into an agreement with all Series A Custom Convertible Preferred shareholders to repurchase the remaining outstanding full amount of approximately $5.0 million. Such repurchase will be made at par ($1,000 per share) plus accrued interest of five percent per annum. The Company anticipates the repurchase will close on or before October 16, 1998. Approximately 1.5 million of the original 6.5 million issue, has previously been converted into common shares. Interim president and chief executive officer Mitchell Kelly said, ''We are very pleased to have negotiated an early repurchase of the Preferred stock at par plus accrued interest. We continue to be focused on our key initiatives including hormone replacement therapies and the anti-microbial agents announced last week.'' He went on to say that the Company will evaluate its interim and long-term financing needs and will consider equity financings and collaborative arrangements with corporate partners along with other sources of funding. Novavax's clinical development efforts focus on the $2.0 billion market for hormone replacement therapy, utilizing topical drugs in cosmetic-like cream formulations. Novavax's two lead topical drugs are: ESTRASORB(TM) -- a patchless estrogen replacement cream, and ANDROSORB(TM) -- a cosmetic- like cream for testosterone replacement therapy in testosterone-deficient men. Also in pre-clinical development is Helicore(TM) -- a non-antibiotic, anti-bacterial product designed to eradicate H. pylori, the intestinal bacterium responsible for most cases of peptic ulcer disease. Novavax recently announced results of certain pre-clinical studies conducted as part of a subcontract to the University of Michigan. These studies indicated that the Company's anti-microbial technology may effectively inactivate anthrax spores and the influenza A virus. Funding for these studies has come from DARPA's Unconventional Pathogen Countermeasures Program. The same technology is currently being tested for additional applications, such as spermicides. In collaboration with the National Institute of Health, spermicidal testing of several of Novavax's emulsions will begin either late 1998 or early 1999. Novavax, Inc. is a biopharmaceutical drug delivery company headquartered in Columbia, Maryland. In addition to historical information, statements made in this press release that state the Company's or management's intentions, hopes, beliefs, expectations or predictions of the future are forward looking statements. Forward looking statements may involve risks and uncertainties, including, but not limited to, uncertainties related to the company's early stage of development and clinical trials and marketability. These factors are more fully discussed in the company annual report on form 10-K/A for the year ended December 31, 1997 and form 10Q for the quarter ended June 30, 1998. SOURCE: Novavax, Inc.